Clinical trials
Locally Advanced Cervical Cancer clinical trials
Below are recruiting locally advanced cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 406 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06384560RecruitingPhase 1/Phase 2
Triple therapy before surgery for pancreatic cancer
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
AmsterdamAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT06251115Recruiting
Study of QY-1-T for advanced HBV-related liver cancer
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
La Jolla, CaliforniaAges 18–130 - NCT04159142RecruitingPhase 2
Testing two chemo combos for advanced triple-negative breast cancer
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Shijiazhuang, HebeiAges 18–70 - NCT06620835RecruitingPhase 2
Optimizing local treatments for ALK-positive lung cancer on brigatinib
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
BrestAges 18 years+ - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT06801665RecruitingPhase 2
Fecal transplant plus immunotherapy and chemotherapy for colon cancer with liver spread
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
ChangzhouAges 18–75 - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT05954442RecruitingPhase 3
Everolimus plus chemo for advanced triple-negative breast cancer
This Phase 3 study tests whether adding everolimus to chemotherapy (chosen by the treating team) can improve outcomes in advanced triple-negative breast cancer, specifically a subtype linked to PAM pathway changes. It may help patients who have not yet had treatment for advanced/metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT07467629RecruitingPhase 1
Study of QLS5212 for people with advanced solid tumors
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
TaiyuanAges 18 years+ - NCT06490068RecruitingPhase 2
LTC004 with toripalimab for immunotherapy-resistant solid tumors
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
BeijingAges 18–75 - NCT05412589RecruitingPhase 2
Testing three cancer medicines for advanced liver cancer
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
Guangzhou, GuangdongAges 18–75 - NCT05981001RecruitingPhase 1/Phase 2
Experimental cell therapy for advanced HER2-negative breast cancer
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Guangzhou, GuangdongAges 18–70 - NCT06121557RecruitingPhase 1
Immune cells from lymph nodes for advanced HER2-negative breast cancer
This trial tests a treatment using your own immune cells taken from lymph nodes near the tumor. The cells are grown in a lab and given back to you to fight cancer, along with another drug chosen by your doctor.
Guangzhou, GuangdongAges 18–70
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced cervical cancer?
- Yes. Clin2 currently lists 406 recruiting locally advanced cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced Pancreatic Cancer
- Locally Advanced Gastric Cancer
- Locally Advanced Cervical Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.